Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7‐year experience

  title={Levodopa/carbidopa intestinal gel infusion in advanced Parkinson's disease: a 7‐year experience},
  author={M. Zibetti and A. Merola and C. Artusi and L. Rizzi and S. Angrisano and D. Reggio and C. Angelis and M. Rizzone and L. Lopiano},
  journal={European Journal of Neurology},
Levodopa/carbidopa intestinal gel (LCIG) infusion is nowadays becoming an established therapeutic option for advanced Parkinson's disease (PD) patients with fluctuating symptoms unresponsive to conventional oral treatment. As the implementation of LCIG therapy is increasing, there is a need for safety and efficacy data from current clinical practice. 

Paper Mentions

Observational Clinical Trial
Levodopa-carbidopa intestinal gel (LCIG) infusion has demonstrated to improve motor fluctuations. The aim of this study is to assess the long-term safety and effectiveness of… Expand
ConditionsParkinson Disease
Levodopa/Carbidopa Intestinal Gel Long‐Term Outcome in Parkinson's Disease: Focus on Dyskinesia
Levodopa‐carbidopa intestinal gel (LCIG) treatment has shown variable effect on dyskinesia in Parkinson's disease (PD).
Levodopa/carbidopa intestinal gel infusion and weight loss in Parkinson's disease
Weight loss (WL) is a frequent yet under‐recognized complication of levodopa/carbidopa intestinal gel (LCIG) infusion, as well as a milestone of Parkinson's disease (PD) disability progression. TheExpand
Peripheral neuropathy associated with levodopa–carbidopa intestinal infusion: a long‐term prospective assessment
This study main objective is to prospectively report the 2‐year incidence of PNP in patients treated with LCIG. Expand
Integrated safety of levodopa‐carbidopa intestinal gel from prospective clinical trials
Continuous administration of levodopa‐carbidopa intestinal gel (carbidopa‐levodopa enteral suspension) through a percutaneous endoscopic gastrojejunostomy is a treatment option for advanced ParkinsonExpand
Long‐term safety and effectiveness of levodopa‐carbidopa intestinal gel infusion
Assessment of the long‐term safety and effectiveness of LCIG infusion in advanced Parkinson's disease patients with motor fluctuations and its effect in nonmotor symptoms is assessed. Expand
Long‐term safety and efficacy of levodopa‐carbidopa intestinal gel in advanced Parkinson's disease
Long‐term safety and efficacy outcomes from an open‐label phase 3 treatment program for advanced Parkinson's disease patients through continuous delivery of levodopa via percutaneous endoscopic gastrojejunostomy are reported. Expand
Carbidopa/levodopa enteral suspension in advanced Parkinson’s disease: a guide to its use
In clinical trials in adults with advanced Parkinson’s disease, carbidopa/levodopa ES provided significantly greater improvements in motor fluctuations and troublesome dyskinesia than oral immediate-release carbidOPA/ levodopa over 12 weeks, and had sustained efficacy in longer-term, open-label studies. Expand
Levodopa/carbidopa intestinal gel: an effective formulation for the management of advanced Parkinson's disease
Levodopa/carbidopa intestinal gel is one option that may offer a therapeutic benefit as significant as that of deep brain stimulation, and to a broader spectrum of PD patients, according to the pharmacological properties, efficacy, and risks and complications. Expand
Levodopa-carbidopa enteral suspension in advanced Parkinson’s disease: clinical evidence and experience
There are also observations that LCIG may be effective treatment for nonmotor symptoms (NMS although the evidence is limited, and there is a need for further research on the efficacy of LCIG in reducing NMS, dyskinesia and improving QoL. Expand
Weight loss and decubitus duodenal ulcer in Parkinson’s disease treated with levodopa–carbidopa intestinal gel infusion
Apparently, unexplained weight loss is a common symptom experienced by patients affected by Parkinson’s disease, especially in those treated by levodopa–carbidopa infusion gel (LCIG) with a poorExpand


Levodopa/carbidopa intestinal gel infusion long‐term therapy in advanced Parkinson’s disease
Background:  Infusion of levodopa/carbidopa intestinal gel (Duodopa®; Abbott) was introduced in Sweden in 1991 as an experimental treatment in advanced Parkinson’s disease and obtained EU approval inExpand
Malnutritional neuropathy under intestinal levodopa infusion
It is assumed that LCIG can provoke PNP most likely of malnutritional origin, and the assessment of predisposing factors before treatment as well as neurophysiological and laboratory screenings appear necessary. Expand
Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease
Continuous intraduodenal infusion of the levodopa/carbidopa enteral gel as monotherapy is safe and clinically superior to a number of individually optimized combinations of conventional oral and subcutaneous medications in patients with motor fluctuations. Expand
Enteral Levodopa/Carbidopa Infusion in Advanced Parkinson Disease: Long-term Exposure
Objectives: In patients with advanced Parkinson disease, levodopa/carbidopa formulated as a gel suspension (Duodopa) permits continuous delivery into the small intestine using a portable pump,Expand
Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life
This is the first demonstration that a levodopa‐based continuous dopaminergic stimulation is beneficial for NMS and health‐related quality of life in PD in addition to the reduction of motor fluctuations and dyskinesias. Expand
Prospective assessment of peripheral neuropathy in Duodopa‐treated parkinsonian patients
Although peripheral neuropathies (PN) have been described in patients with Parkinson's disease (PD) treated with oral dopaminergic therapies, anecdotal reports of subacute severe PN have beenExpand
Severe gastrointestinal complications in patients with levodopa/carbidopa intestinal gel infusion
A considerable potential is suggested of GI SAEs under LCIG, in line with gastroenterological reports on common (Jet-)PEG safety, and only experienced endoscopists affiliated to the LCIG team should implement the therapy to minimize PEG-related problems. Expand
Long-term duodenal levodopa infusion in Parkinson’s disease: a 3-year motor and cognitive follow-up study
Continuous enteral levodopa infusion achieves a reduction of motor fluctuations and dyskinesias improving patients’ QoL, despite the progression of PD motor symptoms and a significant decline in cognitive functions in a sub-group of patients. Expand
Effect and safety of duodenal levodopa infusion in advanced Parkinson’s disease: a retrospective multicenter outcome assessment in patient routine care
The results demonstrate significant and sustained benefit over a long observation period in motor complications and in quality of life following a change from oral pulsatile to continuous levodopa delivery. Expand
Duodopa® treatment for advanced Parkinson's disease: a review of efficacy and safety.
  • D. Nyholm
  • Medicine
  • Parkinsonism & related disorders
  • 2012
The large majority of studies have reported that Duodopa® is clinically effective in relieving the symptoms of advanced PD and improving QoL in comparison with conventional therapy. Expand